Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug GMP Report > Nephron Gets 483 for Inadequate Sterility Testing of Asthma Drugs

Drug GMP Report

January 2012

Nephron Gets 483 for Inadequate Sterility Testing of Asthma Drugs

Nephron Pharmaceuticals may have inadvertently distributed batches of asthma medicine befouled by Bacillus bacteria, an FDA Form 483 states.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

FDA Inspection Flap Prompts Alexion Risk Assessment Reform Gilead Form 483 Provides Insight into FDA’s Rejection of HIV Drugs FDA Rejects Allergan’s Levadex Due to CMO Concerns Novartis 483 Highlights Rocky Remediation at Nebraska Plant

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.